[1] Miller MJ, Foy KC, Kaumaya PT. Cancer immunotherapy: present status, future perspective, and a new paradigm of peptide immunotherapeutics[J]. Discov Med, 2013, 15(82):166-176. [2] Yao S, Chen L. Adaptive resistance: A tumor strategy to evade immune attack[J]. Eur J Immunol, 2013, 43(3):576-579. [3] Tian X, Zhu M, Nie G. How can nanotechnology help membrane vesicle-based cancer immunotherapy development? [J]. Hum Vaccin Immunother, 2013, 9(1):222-225. [4] Shook DR, Leung W. Natural killer cell therapy for cancer: delivering on a promise[J]. Transfusion, 2013, 53(2):245-248. [5] Varchetta S, Oliviero B, Mavilio D, et al. Different combinations of cytokines and activating receptor stimuli are required for human natural killer cell functional diversity[J]. Cytokine, 2013, 62(1):58-63. [6] Francesehetti M, Pievani A, Borleri G, et al. Cytokine-induced killer cells are term inally differentiated activated CD8 cytotoxic TEMRA lymphocytes[J]. Exp Hematol, 2009, 37(5): 616-628. [7] Bruno A, Focaccetti C, Pagani A, et al. The proangiogenic phenotype of natural killer cells in patients with non-small cell lung cancer[J]. Neoplasia, 2013, 15(2):133-142. [8] Shen X, Zhou J, Hathcock KS, et al. Persistence of tumor infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length[J]. J Immunother, 2007, 30(1):123-129. [9] Weng DS, Zhou J, Zhou QM, et al. Minimally invasive treatment combined with cytokine-induced killer ceils therapy lower the short•-term recurrence rates of hepatocellular carcinomas[J]. J Inmmnother, 2008, 31(1): 63-71. [10] Kuci S, Voss B, Rettinger E, et al. Eficient lysis of rhabdomyosarcoma cells by cytokine-induced killer cells:implications for adoptive immunotherapy after allogeneic stem cell transplantation[J]. Haematologiea, 2010, 95(9): 1579-1586. [11] Nishimura R, Baker J, Beilhack A, et al. In vivo trafficking and survival of cytokine—induced killer cells resulting in minimal GVHD with retention of antitumor activity[J]. Blood, 2008, 112(6): 2563-2574. [12] Kornacker M, Moldenhauer G, Herbst M, et al. Cytokine-induced killer cells against autologous CLL: direct cytotoxic effects and induction of immune accessory molecules by interferon-gamma[J]. Int J Cancer, 2006, 119(6): 1377-1382. [13] Linn YC, Lau SK, Liu BH, et al. Characterization of the recognition and functional heterogeneity exhibited by cytokine-induced killer cell subsets against acute myeloid leukaemia target cell[J]. Immunology, 2009, 126(3):423-435. [14] Kornacker M, Verneris M, Kornacker B, et al. The apoptotic and proliferative fate of cytokine-induced killer cells after redirection to tumor cells with bispecific Ab[J]. Cytotherapy, 2006, 8(1):13-23. [15] Pievani A, Belussi C, Klein C, et al. Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodies[J]. Blood, 2011, 117(2):510-518. [16] Alvarnas JC, Linn YC, Hope EG, et al. Expansion of cytotoxic CD3+ CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation[J]. Biol Blood Marrow Transplant, 2001, 7(4):216-222. [17] 姚春, 宋善俊. 血CIK细胞对耐药白血病细胞体外杀伤效应及其机制的研究[J]. 临床血液学杂志, 2008, 21(1):369-372.(下转393页) [18] (上接408页)Linn YC, Niam M, Chu S, et al. The anti-tumour activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies[J].Bone Marrow Transplant, 2012, 47(7):957-966. [19] Jiang JT, Xu N, Wu C, et al. Treatment of advanced gastriccancer by chemotherapy combined with autologous cytokine-induced killer cells[J].Anticancer Res, 2006, 26(3): 2237-2242. [20] Zhao M, Wu PH, Zeng YX, et al. Cytokine-induced killer cell fusion to lower recurrence of hepatocellula carcinoma after transcatheter arterial chemoembolization sequentially combined with radiofrequency ablation: a randomized trial[J].中华医学杂志,. 2006, 86(26):1823-1828. [21] 鲍锋, 除岩, 尹富华,等. CIK细胞过继免疫治疗中晚期恶性肿瘤的临床研究[J]. 辽宁医学杂志, 2003, 17(4:)187-188. [22] Jennifer M. Reiman, Maciej Kmieciak, et al. Tumor immunoediting and immunosculpting pathways to cancer progression[J]. Semin Cancer Biol, 2007, 17(4):275-287. [23] Bui JD, Schreiber RD. Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes [J]. Curr Opin Immunol, 2007, 19(4):203-208. |